Neurology and Cognitive Neuroscience October 18-19, 2018
October 18 - October 19
ConferenceSeries Ltd invites all the participants from all over the world to attend ‘Cognitive Neuroscience 2018 during October 18-19,2017 at Warsaw, Poland which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.
Neurocognitive disorders includes Alzheimer’s disease, is one of the biggest global public health challenges facing our generation. Worldwide, at least 46 million people are living with dementia this number is expected to double by 2030 and more than triple by 2050 to 116 million. Much of the increase will be in developing countries like Western Europe and North America. Already 62% of people with dementia live in developing countries. Today, over 35 million people worldwide currently live with the condition. This number is expected to double by 2030 and more than triple by 2050 to 116 million. No treatments available to slow or stop the brain damage caused by Alzheimer’s disease, several medications can temporarily help improve the symptoms of dementia for some people. In two decades, it is estimated that 1.4 million Canadians will have dementia, costing the economy almost $300 billion per year. Globally, dementia cost $600 billion a year.
The term Dementia describes a loss of mental ability (cognitive impairment) associated with gradual death of brain cells. Vascular Dementia can be caused by a number of different diseases, usually neurodegenerative diseases, such as Alzheimer’s disease, front temporal dementia and dementia with Lewy bodies. Vascular dementia is caused when the brain’s blood supply is restricted or stopped, leading brain cells to die.
Delirium is defined as a transient, usually reversible, cause of cerebral dysfunction and manifests clinically with a wide range of neuropsychiatric abnormalities. It can occur at any age, but it occurs more commonly in patients who are elderly and have compromised mental status.
Delirium occurs in 30% of those in emergency departments. Occurrence rates vary from 11-42% and it is the most common complication of hospitalization in the elderly population. The incidence is also higher in those with pre-existing cognitive impairment. The prevalence is higher in patients with malignancy and HIV. Despite these facts, delirium remains under diagnosed and poorly managed – only 20-50% is recognized by healthcare professionals.
Why to attend?
Cognitive Neuroscience 2018 will provide an opportunity for all stakeholders working on Alzheimer’s disease and Dementia to talk about their work. Neurocognitive disorders will congregate renowned speakers, principal investigators, experts, neurologist’s and Dementia researchers from both academia and health care industry will join together to discuss their views and research. The conference will be comprised of sessions by world class experts in the field of neurology. In Neurocognitive disorders international symposiums, B2B meetings, international workshops will also be organized to discuss the specific topics in the field of Dementia and Neurology.
- Neurologists and Directors
- Health care professionals
- Industrial Experts
- Nutritional Scientists
- Lecturers and Students from Academia in the study of Dementia
- Students from Academia in the research of Neurology